Your browser doesn't support javascript.
loading
Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia.
Huschart, Emily; Miller, Holly; Salzberg, Dana; Campbell, Courtney; Beebe, Kristen; Schwalbach, Charlotte; Magee, Kyrie; Adams, Roberta H; Ngwube, Alexander.
Afiliação
  • Huschart E; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
  • Miller H; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
  • Salzberg D; Mayo Clinic Arizona, Phoenix, Arizona, USA.
  • Campbell C; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
  • Beebe K; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
  • Schwalbach C; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
  • Magee K; Mayo Clinic Arizona, Phoenix, Arizona, USA.
  • Adams RH; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
  • Ngwube A; Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
Pediatr Hematol Oncol ; 38(2): 154-160, 2021 Mar.
Article em En | MEDLINE | ID: mdl-33150833
ABSTRACT
Post-hematopoietic stem cell transplantation (HSCT) maintenance therapy using azacitidine and prophylactic donor lymphocyte infusions (DLI) was implemented for high-risk acute myeloid leukemia. Azacitidine was started on day +60 as a 5 day course every 28 days for 6 cycles. DLI was given every 6 weeks for 3 doses starting after day +120. Ten patients were treated on this protocol. With a 90% one-year disease free survival, we report this post-HSCT maintenance therapy is feasible, safe, and well tolerated.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda / Transfusão de Linfócitos / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Antimetabólitos Antineoplásicos Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Hematol Oncol Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Azacitidina / Leucemia Mieloide Aguda / Transfusão de Linfócitos / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Antimetabólitos Antineoplásicos Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Pediatr Hematol Oncol Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos